[{"orgOrder":0,"company":"Avextra","sponsor":"German Pain Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Avextra","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avextra \/ German Pain Association","highestDevelopmentStatusID":"1","companyTruncated":"Avextra \/ German Pain Association"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Induced Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"1","companyTruncated":"Evotec \/ Bristol Myers Squibb"}]

Find Novel Neurology Drugs in Clinical Development in GERMANY

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : The company aims to focus on the clinical advancement of THC , a partial agonist of the CB1 receptor with Cannabidiol, evaluated for chemotherapy-induced neuropathic pain treatment.

                          Product Name : THC:CBD

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          January 23, 2024

                          Lead Product(s) : Tetrahydrocannabinol,Cannabidiol

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : German Pain Association

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Discovery Europe
                          Not Confirmed
                          Discovery Europe
                          Not Confirmed

                          Details : This partnership pursues an innovative approach to identifying and creating novel medicines using several of Evotec's technology technologies in tandem with the human iPSC-based platform.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 01, 2020

                          Lead Product(s) : Induced Pluripotent Stem Cell

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Bristol Myers Squibb

                          Deal Size : $6.0 million

                          Deal Type : Collaboration

                          blank